Synexa Life Sciences, a Dutch bioanalysis firm, has bought Alderley Analytical Ltd, based near Macclesfield, for an undisclosed sum.
The purchase is the next step for Synexa as it looks to expand its core business of analyzing DNA, RNA, protein, cell, and tissue.
Alderley specializes in mass spectrometry and ligand binding assays, offering a full range of bioanalytical services to support discovery, preclinical, and clinical drug development projects in small molecules, large molecules, peptides, oligonucleotides, and biomarkers.
Founded in 2013 and operational since 2014, Alderley now employs around 60 highly qualified staff and has over 200 clients, establishing itself as a key player in supporting drug development programmes. It recently relocated to specially designed laboratories at Tytherington Business Park near Macclesfield.
CEO of Synexa Life Sciences, Emile Lens, said: “Welcoming Alderley Analytical to our group is a pivotal step in Synexa’s growth strategy, enhancing our capabilities in bioanalytical services and broadening our geographic reach as a leading European specialist biomarker and bioanalysis services company.
“By combining two very complementary companies, the group can now offer an even more comprehensive range of services to an enlarged customer base, both in large and small molecule drug development and ranging from pre-clinical work to phase III clinical studies. We are delighted to welcome the Alderley team to Synexa and look forward to combining our strengths.”
Paul Holme, CEO and Co-Founder of Alderley Analytical, said: “We are thrilled to join forces with Synexa Life Sciences. This step represents a significant opportunity to enhance our teams’ bioanalytical services and broaden our impact on drug development. We are excited by the new possibilities of providing greater value to our customers and supporting the further advancement of innovative therapies.”
The sale marks a successful exit for North West fund manager River Capital, which made what it called a “six-figure investment” in the firm in July 2015 through the North West Biomedical Fund, which was initially managed by SPARK Impact and which has since operationally merged with River Capital.
The investment has yielded “substantial returns,” the fund said.
Jerry Mobbs, Portfolio Director at River Capital, said: “Our investment in Alderley Analytical exemplifies River Capital’s commitment to supporting innovative businesses in the North West. The company’s growth from a startup to a major player in the bioanalytical services sector is a testament to the hard work of its founders and the potential of the region’s biomedical industry.”